source
- Windward Bio targets $204M Nasdaq IPO to fund Chinese respiratory drug programWindward Bio, a biotech backed by Sanofi, announced plans to go public on Nasdaq with an offering of 10.3 million shares priced between $16 and $18 each. The company expects net proceeds of about $…
- Global liver experts agree on definition of acute-on-chronic liver failureLiver doctors from many countries have reached a common definition for acute-on-chronic liver failure, a serious complication that occurs when an existing liver disease is suddenly worsened by an a…